Movement Alert|BEONE MEDICINES Declines 3.01% in Regular Trading, CEO Sells Shares Worth Nearly $20 Million

Market Focus
08/14

On August 14, BEONE MEDICINES (06160.HK) fell 3.01% in regular trading to HKD 213.0, with turnover of HKD 272 million.

On the news front, company co-founder and CEO John Oyler sold approximately 713,600 ordinary shares on August 12 at an average price of USD 27.55 per share, totaling approximately USD 19.66 million. Following the disposal, his stake decreased from 3.86% to 3.82%. The selling pressure from executive share reduction weighed on market sentiment.

Within the Biotechnology sector where BEONE MEDICINES belongs, the broader sector showed notable weakness. Among individual stocks, AKESO down 5.55%, ZAI LAB down 5.10%, REMEGEN down 1.39%, INNOVENT BIO down 0.26%, and 3SBIO up 0.06%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10